A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines

An accurate and rapid reverse HPLC method has been developed and validated for the simultaneous quantification of lamivudine, nevirapine, and tenofovir disoproxil fumarate. Suitable separation was achieved on Phenomenex Synergi C18 (250 × 4.6 mm, 4 μm) using mobile phase, methanol (50%): ammonium ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Phoebe Esinam Goku, Emmanuel Orman, Anna Naa Kwarley Quartey, Joseph Kwasi Adu, Reimmel Kwame Adosraku
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Chemistry
Online Access:http://dx.doi.org/10.1155/2020/4618360
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849304817159110656
author Phoebe Esinam Goku
Emmanuel Orman
Anna Naa Kwarley Quartey
Joseph Kwasi Adu
Reimmel Kwame Adosraku
author_facet Phoebe Esinam Goku
Emmanuel Orman
Anna Naa Kwarley Quartey
Joseph Kwasi Adu
Reimmel Kwame Adosraku
author_sort Phoebe Esinam Goku
collection DOAJ
description An accurate and rapid reverse HPLC method has been developed and validated for the simultaneous quantification of lamivudine, nevirapine, and tenofovir disoproxil fumarate. Suitable separation was achieved on Phenomenex Synergi C18 (250 × 4.6 mm, 4 μm) using mobile phase, methanol (50%): ammonium acetate buffer (adjusted to pH 2.80) (40%): acetonitrile (10%) in an isocratic mode. The drugs were detected at 270 nm with a flow rate of 1.0 ml/min, and the retention times were found to be 3.26, 5.42, and 7.55 minutes for lamivudine, nevirapine, and tenofovir disoproxil fumarate, respectively. The developed method was validated per ICH guidelines. Good linearity was obtained within the concentration ranges of 10–59 µg/ml, 7–42 µg/ml, and 15–90 µg/ml with a correlation coefficient of not less than 0.990. The % RSD values for precision (intraday and interday) and accuracy studies were found to be less than 2%. The results obtained from quantitative analysis conform to USP content requirements for marketed tablet dosage forms, RICOVIR-LN, and tenofovir disoproxil fumarate/lamivudine tablets. The method is therefore useful for routine quality control of antiretroviral tablet dosage forms containing tenofovir disoproxil fumarate, lamivudine, and nevirapine.
format Article
id doaj-art-3cb6490f2ac0464c96482a192534861b
institution Kabale University
issn 2090-9063
2090-9071
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Chemistry
spelling doaj-art-3cb6490f2ac0464c96482a192534861b2025-08-20T03:55:37ZengWileyJournal of Chemistry2090-90632090-90712020-01-01202010.1155/2020/46183604618360A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral MedicinesPhoebe Esinam Goku0Emmanuel Orman1Anna Naa Kwarley Quartey2Joseph Kwasi Adu3Reimmel Kwame Adosraku4Department of Pharmaceutical Sciences, School of Pharmacy, Central University, Accra 23321, GhanaDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Health and Allied Sciences, Ho 23321, GhanaDepartment of Pharmaceutical Sciences, School of Pharmacy, Central University, Accra 23321, GhanaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 23321, GhanaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 23321, GhanaAn accurate and rapid reverse HPLC method has been developed and validated for the simultaneous quantification of lamivudine, nevirapine, and tenofovir disoproxil fumarate. Suitable separation was achieved on Phenomenex Synergi C18 (250 × 4.6 mm, 4 μm) using mobile phase, methanol (50%): ammonium acetate buffer (adjusted to pH 2.80) (40%): acetonitrile (10%) in an isocratic mode. The drugs were detected at 270 nm with a flow rate of 1.0 ml/min, and the retention times were found to be 3.26, 5.42, and 7.55 minutes for lamivudine, nevirapine, and tenofovir disoproxil fumarate, respectively. The developed method was validated per ICH guidelines. Good linearity was obtained within the concentration ranges of 10–59 µg/ml, 7–42 µg/ml, and 15–90 µg/ml with a correlation coefficient of not less than 0.990. The % RSD values for precision (intraday and interday) and accuracy studies were found to be less than 2%. The results obtained from quantitative analysis conform to USP content requirements for marketed tablet dosage forms, RICOVIR-LN, and tenofovir disoproxil fumarate/lamivudine tablets. The method is therefore useful for routine quality control of antiretroviral tablet dosage forms containing tenofovir disoproxil fumarate, lamivudine, and nevirapine.http://dx.doi.org/10.1155/2020/4618360
spellingShingle Phoebe Esinam Goku
Emmanuel Orman
Anna Naa Kwarley Quartey
Joseph Kwasi Adu
Reimmel Kwame Adosraku
A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines
Journal of Chemistry
title A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines
title_full A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines
title_fullStr A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines
title_full_unstemmed A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines
title_short A Simple RP-HPLC Method to Simultaneously Assay the Contents of Lamivudine, Tenofovir, and Nevirapine in Fixed Dose Combined Oral Antiviral Medicines
title_sort simple rp hplc method to simultaneously assay the contents of lamivudine tenofovir and nevirapine in fixed dose combined oral antiviral medicines
url http://dx.doi.org/10.1155/2020/4618360
work_keys_str_mv AT phoebeesinamgoku asimplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT emmanuelorman asimplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT annanaakwarleyquartey asimplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT josephkwasiadu asimplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT reimmelkwameadosraku asimplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT phoebeesinamgoku simplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT emmanuelorman simplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT annanaakwarleyquartey simplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT josephkwasiadu simplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines
AT reimmelkwameadosraku simplerphplcmethodtosimultaneouslyassaythecontentsoflamivudinetenofovirandnevirapineinfixeddosecombinedoralantiviralmedicines